Orilissa

Active Ingredient(s): Elagolix Sodium
FDA Approved: * July 23, 2018
Pharm Company: * ABBVIE INC
Category: Women's Health / Fertility

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Orilissa Overview

Elagolix, sold under the brand name Orilissa, is a gonadotropin-releasing hormone antagonist (GnRH antagonist) medication which is used in the treatment of pain associated with endometriosis in women.[1][4][2][5][6] It is also under development for the treatment of uterine fibroids in women.[6] The medication was under investigation for the treatment of prostate cancer and enlarged prostate in men ...

Read more Orilissa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Elagolix

Recent Orilissa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Elagolix Sodium
  • Tablet: 150mg, 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Orilissa: (2 results)

Sorted by National Drug Code
  • 0074-0038 Orilissa 150 mg Oral Tablet, Film Coated by Abbvie Inc.
  • 0074-0039 Orilissa 200 mg Oral Tablet, Film Coated by Abbvie Inc.

Other drugs which contain Elagolix Sodium or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 14 November 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA